Longboard pharmaceuticals announces initiation of first-in-human phase 1 clinical study of lp659 in adult healthy volunteers

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a phase 1 randomized, double-blind, placebo-controlled, sad clinical study of lp659. lp659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (s1p) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neur.
LBPH Ratings Summary
LBPH Quant Ranking